Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
Tonix Pharmaceuticals will present a poster analyzing Phase 3 data on TONMYA (cyclobenzaprine HCl sublingual tablets) in fibromyalgia at the IASP 2026 World Congress on Pain in Bangkok, October 26-30. The poster, presented by SVP of Medical Affairs Errol Gould on October 27, examines TONMYA's effects on fibromyalgia symptoms and physical function; TONMYA was FDA-approved August 15, 2025 and launched in the U.S. November 17, 2025.
Key figures
- Congress
- IASP 2026 World Congress on Pain, Bangkok, Thailand, October 26-30, 2026
- Poster number
- 157
- Presentation date
- October 27, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.